Therapy News and Research

RSS

Discovery provides additional key insights into the biology of Multiple Sclerosis

A Griffith University medical scientist is part of an international team which has made a key discovery in the effort to find the cause and cure of Multiple Sclerosis.

30 Sep 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Study examines new method for beating PTSD related to childhood sexual abuse

A new method for overcoming post-traumatic stress disorder related to childhood sexual abuse has been tested and findings are published in the current issue of Psychotherapy and Psychosomatics.

30 Sep 2013

Minimally invasive treatments for lumbar spinal stenosis: an interview with James Corbett, President & Chief Executive Officer of Vertos Medical

Lumbar spinal stenosis (LSS) is a degenerative, age-related narrowing of the lower spinal canal that causes pressure on the nerves, leading to pain and reduced mobility. Symptoms include pain, numbness, or tingling in the lower back, legs, or buttocks, which limits your ability to stand or walk.

30 Sep 2013

Biology of tumour more important than primary site, say researchers

Identifying the molecular profile of a tumour where the primary site is unknown is crucial to the choice of treatment, the 2013 European Cancer Congress, will hear on Monday.

30 Sep 2013

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

New results from a trial of an antibody that helps the immune system to recognise and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers.

30 Sep 2013

AMGEN announces additional results from talimogene laherparepvec Phase 3 trial

AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).

30 Sep 2013

New treatment methods aim to help people reduce binge-eating behavior

Two new treatment methods under investigation at Drexel University aim to help people reduce binge-eating behavior.

30 Sep 2013

Colorectal cancer in younger people appears to be more aggressive

Younger patients with colorectal cancer that has spread (metastasised) to other parts of the body represent a high-risk group that is less likely to respond to anti-cancer treatments.

29 Sep 2013

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research to be presented today (Sunday) at the 2013 European Cancer Congress.

29 Sep 2013

Doing yoga during menopause linked to less insomnia

Taking a 12-week yoga class and practicing at home was linked to less insomnia-but not to fewer or less bothersome hot flashes or night sweats. The link between yoga and better sleep was the only statistically significant finding in this MsFLASH (Menopause Strategies: Finding Lasting Answers for Symptoms and Health) Network randomized controlled trial.

29 Sep 2013

c-Fos oncogene cab be important target for understanding and treatment of cancer

The c-Fos oncogene has traditionally been linked to cellular activities related to cancer, such as cell division, differentiation-conversion from one cell type to another-or survival. Any alteration of these activities can set off the development of tumours, which has made c-Fos an important target for the understanding and treatment of cancer.

29 Sep 2013

Studies show evidence-guided molecular profiling improves treatment for hard-to-treat cancers

Caris Life Sciences announced today data from two studies presented at the 2013 European Cancer Congress, which demonstrate the potential of evidence-guided molecular profiling to immediately improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) origins as well as rare tumors and cancers that have been refractory to treatment.

29 Sep 2013

White paper addresses needs, challenges and solutions for improving mCRC treatment

The Angiogenesis Foundation released a white paper at the 2013 European Cancer Congress that addresses the needs, challenges, and proposed solutions for improving treatment of metastatic colorectal cancer, the third most common cancer among men and the second most common among women worldwide.

28 Sep 2013

FDA expands Hizentra administration options for people with primary immunodeficiency

CSL Behring announced today that the U.S. Food and Drug Administration has expanded the administration options for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, to include dosing once every two weeks (biweekly) for people diagnosed with primary immunodeficiency.

28 Sep 2013

Ablynx Nets Another $33.7M From Merck Serono As Partnership Expands

...

27 Sep 2013

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

The prevalence of skin disease exceeds that of obesity, hypertension or cancer. One in three individuals in the United States suffers with a skin disease, with ~2-3% of the American population suffering from psoriasis.

27 Sep 2013

Women should tackle hormonal chaos, seek treatment for perimenopausal symptoms

Women should address the "hormonal chaos" of their 40s and not be afraid to seek treatment for perimenopausal symptoms, advises an internationally recognized expert in reproductive endocrinology from Wake Forest Baptist Medical Center.

27 Sep 2013

Japanese MHLW approves Hizentra for treatment of primary and secondary immunodeficiencies

CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and serious diseases of the immune system.

27 Sep 2013

Genomic instability in CFS is associated with less favorable outcome in patients with CaP

Detailed evaluation of a prostate cancer tumor biopsy may predict treatment outcomes for image-guided radiation therapy (IGRT) or surgery for prostate cancer, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

27 Sep 2013

Therapy News and Research

Discovery provides additional key insights into the biology of Multiple Sclerosis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Study examines new method for beating PTSD related to childhood sexual abuse

Minimally invasive treatments for lumbar spinal stenosis: an interview with James Corbett, President & Chief Executive Officer of Vertos Medical

Biology of tumour more important than primary site, say researchers

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

AMGEN announces additional results from talimogene laherparepvec Phase 3 trial

New treatment methods aim to help people reduce binge-eating behavior

Colorectal cancer in younger people appears to be more aggressive

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

Doing yoga during menopause linked to less insomnia

c-Fos oncogene cab be important target for understanding and treatment of cancer

Studies show evidence-guided molecular profiling improves treatment for hard-to-treat cancers

White paper addresses needs, challenges and solutions for improving mCRC treatment

FDA expands Hizentra administration options for people with primary immunodeficiency

Ablynx Nets Another $33.7M From Merck Serono As Partnership Expands

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

Women should tackle hormonal chaos, seek treatment for perimenopausal symptoms

Japanese MHLW approves Hizentra for treatment of primary and secondary immunodeficiencies

Genomic instability in CFS is associated with less favorable outcome in patients with CaP

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News